HUT73185A - A novel osteoblastic proliferative factor - Google Patents

A novel osteoblastic proliferative factor

Info

Publication number
HUT73185A
HUT73185A HU9502202A HU9502202A HUT73185A HU T73185 A HUT73185 A HU T73185A HU 9502202 A HU9502202 A HU 9502202A HU 9502202 A HU9502202 A HU 9502202A HU T73185 A HUT73185 A HU T73185A
Authority
HU
Hungary
Prior art keywords
novel
proliferative factor
osteoblastic
bone
diseaese
Prior art date
Application number
HU9502202A
Other languages
Hungarian (hu)
Other versions
HU9502202D0 (en
HU217082B (en
Inventor
Akira Kudo
Tohru Nakanishi
Masaharu Takigawa
Original Assignee
Hoechst Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan filed Critical Hoechst Japan
Publication of HU9502202D0 publication Critical patent/HU9502202D0/en
Publication of HUT73185A publication Critical patent/HUT73185A/en
Publication of HU217082B publication Critical patent/HU217082B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention relates to a composition for metabolic bone diseaese and/or bone fractures which comprises a pharmaceutically acceptable carrier and human neurotrophin-3 (NT-3). This invention also relates to a method for the treatment and/or prevention of metabolic bone diseaese or bone fractures which comprises administering to a patient in need of said treatment and/or prevention a medicament containing an effective amount of human neurotrophin-3 (NT-3). <IMAGE>
HU9502202A 1994-07-22 1995-07-21 Use of human neurotrophin-3 for producing pharmaceutical compositions for treating metabolic osteopathiae HU217082B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20125794A JP3738281B2 (en) 1994-07-22 1994-07-22 Novel osteoblast growth factor

Publications (3)

Publication Number Publication Date
HU9502202D0 HU9502202D0 (en) 1995-09-28
HUT73185A true HUT73185A (en) 1996-06-28
HU217082B HU217082B (en) 1999-11-29

Family

ID=16437950

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9502202A HU217082B (en) 1994-07-22 1995-07-21 Use of human neurotrophin-3 for producing pharmaceutical compositions for treating metabolic osteopathiae

Country Status (14)

Country Link
US (1) US6080720A (en)
EP (1) EP0704219B1 (en)
JP (1) JP3738281B2 (en)
KR (1) KR100361717B1 (en)
AT (1) ATE206930T1 (en)
AU (1) AU693567B2 (en)
CA (1) CA2154403A1 (en)
DE (1) DE69523250T2 (en)
DK (1) DK0704219T3 (en)
ES (1) ES2161809T3 (en)
FI (1) FI953514A (en)
HU (1) HU217082B (en)
NO (1) NO952912L (en)
PT (1) PT704219E (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088318A1 (en) 2010-01-15 2011-07-21 University Of Medicine And Dentistry Of New Jersey Use of vanadium compounds to accelerate bone healing
US20140322292A1 (en) 2010-12-10 2014-10-30 Rutgers, The State University Of New Jersey Insulin-mimetics as therapeutic adjuncts for bone regeneration
JP5992917B2 (en) 2010-12-10 2016-09-14 ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー Implantable device coated with insulin mimetic composite and method thereof
WO2013006798A1 (en) 2011-07-06 2013-01-10 University Of Medicine And Dentistry Of New Jersey Vandium compounds as therapeutic adjuncts for cartilage regeneration and repair

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
AU2460595A (en) * 1994-05-06 1995-11-29 Regeneron Pharmaceuticals, Inc. Methods based on the role of neurotrophin 3 in female reproduction

Also Published As

Publication number Publication date
AU693567B2 (en) 1998-07-02
HU9502202D0 (en) 1995-09-28
EP0704219B1 (en) 2001-10-17
JP3738281B2 (en) 2006-01-25
FI953514A0 (en) 1995-07-20
ES2161809T3 (en) 2001-12-16
KR100361717B1 (en) 2003-07-07
DE69523250T2 (en) 2002-07-04
KR960003741A (en) 1996-02-23
PT704219E (en) 2002-03-28
DK0704219T3 (en) 2002-02-04
NO952912D0 (en) 1995-07-21
FI953514A (en) 1996-01-23
EP0704219A3 (en) 1997-12-10
AU2710595A (en) 1996-02-01
ATE206930T1 (en) 2001-11-15
JPH0834744A (en) 1996-02-06
NO952912L (en) 1996-01-23
US6080720A (en) 2000-06-27
DE69523250D1 (en) 2001-11-22
HU217082B (en) 1999-11-29
CA2154403A1 (en) 1996-01-23
EP0704219A2 (en) 1996-04-03

Similar Documents

Publication Publication Date Title
UA29505C2 (en) Pharmaceutical composition for treatment and/or prophylaxis of bone resorption and method of medical treatment and/or prophylaxis of bone resorption in mammals
HUT77380A (en) Use of a pharmaceutical combination for the treatment of multiple sclerosis (ms) and other demyelinating conditions
DE69825292D1 (en) USE OF INOSINE FOR PRODUCING A MEDICINE FOR STIMULATING AXON GROWTH OF CNS NEURONES
RU94027680A (en) Parathyroid hormone and raloxifen for bone mass increase, pharmaceutical composition and method of osseous mass increase
HU9502193D0 (en) Combination treatment for inhibiting bone loss
HK1022835A1 (en) Pharmaceutical composition for treatment of diabetes
MXPA02006679A (en) Pharmaceutical composition.
IL100069A0 (en) Laser radiation method and device for the treatment of body and dental tissues and bone
ES2173111T3 (en) USE OF FENSERINE FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF COGNOSCITIVE DISORDERS.
MX9710252A (en) Use of one or more peptides in a cosmetic composition or for the preparation of a medicament.
ES2160643T3 (en) COMPOSITIONS CONTAINING G-CSF AND PROTEIN OF UNION TO TNF.
SG47451A1 (en) Implantable therapy system
GR3032041T3 (en) Idebenone compositions for treating Alzheimer&#39;s disease.
HUT73185A (en) A novel osteoblastic proliferative factor
BR9710250A (en) Compound pharmaceutical composition and processes for treating a bacterial infection in a patient in need of such treatment and for producing a bromothiacumycin compound
EP0744176A3 (en) Methods for inhibiting bone loss
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
PL328924A1 (en) Method of treating abuse of substances
EP0862442A4 (en) Methods for diagnosis and treatment of bloom&#39;s syndrome
AU639693B2 (en) Laser apparatus for treating bone and tooth tissue
IL103499A0 (en) Pharmaceutical compositions for treating anxiety in benzodiazepine withdrawn patients
SG64899A1 (en) Method and composition for treatment of patients having decompsated liver disease
IT1276706B1 (en) Bicarbonates of 2,6-dimethylaniline derivatives, their use in treatment and pharmaceutical compositions containing them
CA2287903A1 (en) Method for treating medical conditions using a microprocessor-based video game

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees